Description
Book SynopsisFollowing the transition of industrial nations to knowledge economies, the financing of technological innovation has become a central issue in public policy, corporate finance and business management. This detailed book examines the role of intellectual property rights in facilitating the financing of technological innovation as well as the role of policy makers, investors and managers in this process. The book's central finding is that public policy plays a key role in promoting the corporate disclosure of intellectual property-related information to enhance the efficiency of capital markets. This not only reduces the costs of capital for technology-driven firms but ultimately spurs innovation and economic growth.
Intellectual Property Rights and the Financing of Technological Innovation will strongly appeal to research students and academics, policy makers, intellectual property professionals, equity analysts, credit rating analysts and executives in the pharmaceutical industry.
Contents:
1. Introduction
2. The Intangible Economy
3. Patent Information and Corporate Credit Ratings: An Empirical Study of Patent Valuation by Credit Rating Agencies
4. IPR Management and Company Valuation in the Pharmaceutical Industry: An Exploratory Study
5. IPR Management, Corporate Disclosures, and Stock Market Valuations in the Pharmaceutical Industry
6. Towards Forward-looking Financial Reporting
Bibliography
Index
Trade ReviewA major contribution to the literature on the role of intellectual property right (IPR) for the financing of innovation. The book is extensively researched and provides compelling insights for IPR managers, technology investors and policymakers trying to promote the efficiency of capital markets and national systems of innovation. --Knut Blind, Berlin University of Technology, Germany
Table of ContentsContents: 1. Introduction 2. The Intangible Economy 3. Patent Information and Corporate Credit Ratings: An Empirical Study of Patent Valuation by Credit Rating Agencies 4. IPR Management and Company Valuation in the Pharmaceutical Industry: An Exploratory Study 5. IPR Management, Corporate Disclosures, and Stock Market Valuations in the Pharmaceutical Industry 6. Towards Forward-looking Financial Reporting Bibliography Index
